News
Lilly CEO Says Biopharmaceuticals Should Be Included in Transatlantic Trade and Economic Discussions
John C. Lechleiter, Ph.D., chairman, president and chief executive officer of Eli Lilly and Company (NYSE: LLY), urged that biopharmaceuticals be included in transatlantic trade and economic discussions. Lechleiter participated in the American Council on Germany's conference on "The...
News
Pfizer to Explore Strategic Alternatives for its Animal Health and Nutrition Businesses
Pfizer Inc. (NYSE: PFE) is exploring strategic alternatives for its Animal Health and Nutrition businesses based on its recent business portfolio review to determine the optimal mix of businesses for maximizing shareholder value. The...
News
Bristol-Myers Squibb and Innate Pharma Announce Breakthrough Global License Agreement
Bristol-Myers Squibb Company (NYSE: BMY) and Innate Pharma S.A. (Euronext Paris: FR0010331421, IPH) announced a global agreement for the development and commercialization of IPH2102, a novel antibody in Phase I development for the treatment of cancer. ...
News
Amgen and UCB Team Up with NASA on Final Space Shuttle Mission
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) are collaborating with the National Aeronautics and Space Administration (NASA) Ames Research Center to conduct a preclinical test of a sclerostin antibody in an experiment that will take place aboard space...
News
Medical Research Council Finds Antibody Capable of Fighting Flu
An antibody that can fight all types of the influenza A virus has been identified by researchers from the Medical Research Council's National Institute for Medical Research. Studies in fly-infected mice showed that the antibody could...
News
GlaxoSmithKline and Valeant announce US FDA approval of Potiga
GlaxoSmithKline and Valeant Pharmaceuticals International, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Potiga™ (ezogabine) Tablets, a potassium channel opener, as adjunctive treatment of partial-onset seizures in patients aged 18 years and older. ...
News
Paladin And Elan Sign Agreement For New Pain Product
Paladin Labs Inc., a leading Canadian specialty pharmaceutical company, today announced that they have entered into a licensing and distribution agreement under which Paladin has been granted exclusive Canadian rights from an affiliate of Elan Corporation,.. ...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
